Comparison of Cisplatin with Lipoplatin in Terms of Ototoxicity

Efe Serinan, Zekiye Altun, Safiye Aktaş, Emre Çeçen, Nur Olgun

Department of Basic Oncology, Dokuz Eylül University Institute of Oncology, Izmir, Turkey (ES, ZA, SA)
Department of Pediatric Oncology, Dokuz Eylül University Institute of Oncology, Izmir, Turkey (NO)
Department of Pediatric Hematology and Oncology, Harran University School of Medicine, Şanlıurfa, Turkey

ORCID IDs of the authors: E.S. 0000-0002-3682-7590; Z.A. 0000-0002-1558-4534; S.A. 0000-0002-7658-5565; N.O. 0000-0001-9591-0207; E.C. 0000-0003-0330-4715

OBJECTIVE: Cisplatin (CDDP) is an anti-neoplastic agent that has been used in treatments of both pediatric and adult cancers. It has many side effects, such as ototoxicity, nephrotoxicity, and neurotoxicity. Lipoplatin (LIPO) is a nanomolecule with 110 nm diameter and composed of lipids and CDDP. In this study, we aimed to compare the toxic effects of LIPO with CDDP in the cochlear cells with anti-tumoral doses determined in neuroblastoma cells.

MATERIALS and METHODS: House Ear Institute Organ Corti 1 (HEI-OC1), MYC-N amplified KELLY, and MYC-N non-amplified SH-SY5Y human neuroblastoma cells were used in this study. Firstly, anti-tumoral lethal dose 50 (LD50) of LIPO and CDDP were determined using the WST-1 assay in both neuroblastoma cells. Then anti-tumoral doses of CDDP and LIPO were applied on HEI-OC1 cells for evaluating the toxic effects. The apoptotic cell death was measured using flow cytometric analysis of annexin-V/7-amino-actinomycin (7-AAD) and cell cycle tests.

RESULTS: LIPO or CDDP inhibited cell viability in a dose- and time-dependent manner in both neuroblastoma and HEI-OC1 cells. LD50 values were selected as 20 mM for CDDP and 750 mM for LIPO in neuroblastoma cells. After the 48-hour incubation, KELLY cells treated with 20 mM CDDP and 750 mM LIPO had a 53% viability; SH-SY5Y cells treated 20 mM CDDP and 750 mM LIPO had a 45% and 58% viability, respectively; and HEI-OC1 cells treated with 20 mM CDDP and 750 mM LIPO had a 65% and 82% viability, respectively.

CONCLUSION: LIPO showed less toxic effects in the HEI-OC1 cells compared to CDDP at anti-tumoral doses.

KEYWORDS: Neuroblastoma, Hei-Oc1, lipoplatin, cisplatin, ototoxicity

INTRODUCTION

Neuroblastoma is a common malignancy in childhood and originates from the primitive neural crest cells in the sympathetic nervous system [1-3]. The behavior of neuroblastoma varies according to the presence of the tumor and the status of metastasis [4, 5]. Neuroblastoma constitutes about 8-10% of all childhood cancers and is responsible for 15% of childhood cancer-related deaths [3]. In neuroblastoma, the patient’s age, tumor histology and stage, and cytogenetic and molecular genetic markers are the most important prognostic indicators [1].

Cisplatin (CDDP) is an anti-neoplastic agent that has been used in the treatment of both pediatric and adult cancers [1-6]. Although CDDP is used in cancer treatments, it has many side effects, such as ototoxicity, nephrotoxicity, and neurotoxicity [5, 6]. Although nephrotoxicity can be controlled and diminished after CDDP treatment, there is no prevention modality against CDDP ototoxicity in clinical practice [6-9]. CDDP causes damage to the organ of corti in the cochlea, resulting hearing loss, which can lead to social developmental deﬁciencies, such as learning problems, in children. Therefore, ototoxicity is an extremely serious problem in childhood [7]. In previous studies, we reported that CDDP shows toxic effects on House Ear Institute-Organ Corti 1 (HEI-OC1) cells [7, 10].

Liposomal platinum is the most promising drug formulation under clinical conditions [11]. Lipoplatin (LIPO) is a liposomally encapsulated form of CDDP [12]. LIPO is a nanomolecule of 110 nm in diameter, which is composed of lipids and CDDP [13]. LIPO has been
L-glutamine. The cells were incubated at 33°C in a 10% CO₂ (DMEM) containing 10% fetal bovine serum (FBS) and 1% (w/v) L-glutamine. The cells were incubated at 33°C in DMEM (Gibco™) and Rosewell Park Memorial Institute (RPMI)-1640 (Gibco™) containing 10% FBS, 1% penicillin/streptomycin, and 1% L-glutamine. HEI-OC1 cells were incubated at 37°C and 5% CO₂ conditions [6]. All reagents were freshly prepared with media before all experiments. The cell viability was determined using an automatic cell counter with a trypan blue exclusion test.

Detection of Cell Proliferation
The WST-1 assay used to determine cell proliferation is based on the basic principle the conversion of the pink tetrazolium salt (WST-1) to a dark red formazan dye via the succinate-tetrazolium reductase enzyme chain [17]. Mitochondrial dehydrogenase enzyme activity is increased as the number of viable cells increases. As enzyme activity increases, formazan dye production also increases. Therefore, the formazan dye increases in direct proportion to the number of metabolically active cells in a cell culture. Cells were counted and 10⁴ cells/well were seeded with least 6 replicates in a 96-well plate by overnight incubation. The cells were then treated with different concentrations of LIPO and CDDP (10 µM-1000 µM) for 24, 48, and 72 hours. Following the incubation periods, the WST-1 assay was performed by adding 10 µL of WST reagents (Roche) to each well, and HEI-OC1 and KELLY and SH-SY5Y neuroblastoma cells were further incubated at 33°C and 37°C, respectively, for 2 hours. After incubation periods, the absorbances of the cells was measured at 450 nm and the reference wavelength at 630 nm was measured at 630 nm on an ELISA reader (Thermo Scientific). The half-maximal inhibitory or lethal concentrations (IC50 or LD50) of the agents were calculated according to control cells viability.

Detection of Apoptotic Cells
Apoptotic cell death was determined using annexin-V-fluorescein isothiocyanate (FITC)/7-amino-actinomycin D (7-AAD) (BD Biosciences) and Cyclestest™ Plus DNA Reagent Kit (BD Biosciences) in all cells. In the normal cells, phosphatidylserine molecules on the cytoplasmic surface of the cell membrane migrate to the outer surface of the cell membrane in the event of cell apoptosis. Annexin-V can be labeled with FITC, a fluorescent substance, which can bind to the phosphatidylserine on the outer surface of the cell [17]. Thus, the apoptotic cells to which FITC is conjugated with annexin-V can be made visible. The principle of the method is based on the extent apoptosis determination using flow cytometry of cells stained with annexin-V-FITC and 7-AAD, a non-vital dye.

RESULTS
Cell Proliferation Results
The cell viability of KELLY human MYC-N amplified and SH-SY5Y human MYC-N non-amplified neuroblastoma cells treated with different doses of LIPO (10–100 µM) and CDDP (10–1000 µM) was determined using the WST-1 assay. LIPO and CDDP inhibited neuroblastoma cell proliferations in a dose- and time-dependent manner (Figure 1, 2).

The doses of CDDP and LIPO applied for KELLY and SHSY cells were also applied for HEI-OC1 cell and cell viability was determined by the WST-1 assay. Also, proliferations of HEI-OC-1 cells were decreased with lower doses of CDDP but a higher dose of LIPO treatments.

The auditory cells and tumor cells were incubated for 48 hours in the presence of LIPO or CDDP. In KELLY neuroblastoma cells, LIPO was used at 750 µM and CDDP was used at 20 µM concentrations determined from cell proliferation assays. In SH-SY5Y cells, LIPO was used at 750 µM and CDDP used at 20 µM. In the auditory cells, cells were treated with 750 µM LIPO and 20 µM CDDP. After incubation, cells were collected in a 1.5 mL centrifuge tube and centrifuged at 500 x g for 10 minutes. Each cell pellet was re-suspended in 100 µL phosphate-buffered saline (PBS), and subsequently 5 µL of annexin-V and 5 µL 7-AAD were added on the cells. The cells were incubated in the dark at 4°C for 15 minutes according to protocol. After incubation, 400 µL annexin-V binding buffer was added in each tube. Analyses were carried out using a flow cytometer (Accuri, BD) at 488 nm excitation and 530 nm emission wavelengths for annexin-V and 488 nm excitation and 647 nm emission wavelengths for 7-AAD, and evaluated using the BD Accuri C6 Software (BD Biosciences) [18].

Cells at different stages of the cell cycle were determined using Cycletest™ Plus DNA Reagent Kit (BD). After the agent applications, the cells were washed thrice with PBS and re-suspended in the medium, incubated for 15 minutes at room temperature with propidium iodide, and then analyzed using flow cytometry [18, 19].

Statistical Analysis
The Statistical Package for Social Sciences software for Windows, version 15.0, released 2007 (SPSS Inc.; Chicago IL, USA) was used for statistical evaluation of the data. Findings with a p value <0.05 for statistical significance were accepted. Non-parametric Mann-Whitney U test was also used. Each experiment was repeated at least in triplicate for statistical evaluation.

In KELLY MYC-N amplified human neuroblastoma cells, the cell viability decreased at a rate of 41% and 75% with the treatment of 1000 µM CDDP and LIPO, respectively, after 24 hours of incubation (p<0.05; Figure 1).

Cisplatin inhibited 50% cell viability at 20 µM doses, while 750 µM LIPO inhibited 50% cell viability in KELLY cells after 48 hours of incubation (p<0.05; Figure 1).

Also, 20 µM CDDP decreased KELLY cell viability at 33%, but 750 µM LIPO inhibited cell viability at 37% after 72 hours of incubation (p<0.05; Figure 1).
Cisplatin inhibited 50% cell viability at 10 μM doses, while LIPO inhibited cell viability at 750 μM in SH-SYSY cells after 48 hours incubation (p<0.05; Figure 2).

Also, 10 μM CDDP decreased SH-SYSY cell viability at 45%, but 750 μM LIPO inhibited cell viability at 42% after 72 hours of incubation (p<0.05; Figure 2).

In the SH-SYSY MYC-N non-amplified human neuroblastoma cells, cell viability decreased at a rate of 28% and 36% with the treatment of 1000 μM CDDP and LIPO, respectively, after 24 hours of incubation (p<0.05; Figure 2).

Cisplatin inhibited 50% cell viability at 10 μM doses, while LIPO inhibited cell viability at 750 μM in SH-SYSY cells after 48 hours incubation (p<0.05; Figure 2).

Also, 10 μM CDDP decreased SH-SYSY cell viability at 45%, but 750 μM LIPO inhibited cell viability at 42% after 72 hours of incubation (p<0.05; Figure 2).
In this study, the in vitro cytotoxic effects of LIPO and CDDP on HEI-OC1 cells with neuroblastoma cells were also compared. Firstly, HEI-OC1 cells were treated with the same doses of both CDDP and LIPO and the IC50 doses were determined from these experiments.

Moreover, we tested the apoptotic effects of the agents in these cells using the annexin-V and cell cycle analysis.

HEI-OC1 cells treated with 750 µM LIPO for 48 hours had an 82% viability. HEI-OC1 cells treated with 20 µM CDDP for 48 hours had a 65% viability.

Therefore, 20 µM CDDP and 750 µM LIPO concentration applied for 48 hours was designated as the IC50. Treatment with LIPO or CDDP induced a dose-dependent (CDDP, IC50=20 and 50 µM; LIPO IC50=750 and 1000 µM) and time-dependent (48 h) inhibition of cell proliferation.

In the SH-SYSY cells, the cell viability was 57% for LD50 doses of LIPO 750 µM, the lowest dose of CDDP is 50% of deaths from 10 µM achieved, and the dose increases with decreased cell viability. The cell viability was 53% for LD50 doses of LIPO 750 µM and 53% for the 20 µM CDDP in KELLY cells. In the HEI-OC1 cells, 1000 µM LIPO led to 66% cell viability and 50 µM of CDDP decreased the cell viability below 50% (44%).

**Apoptosis Results of the Cells**

We also compared apoptosis level at the IC50 concentration of LIPO and CDDP on KELLY, SH-SYSY, and HEI-OC1 cells. To compare the apoptosis level of LIPO and CDDP, flow cytometry annexin-V/7-AAD and cell cycle assays were used.

LD50 doses of CDDP caused 62.3-77.3% and LIPO caused 38.85-45.6% apoptotic cell death in KELLY cells. In SH-SYSY, LD50 doses of CDDP caused 75.8%-86.9% and LIPO induced 25.3-56.3% apoptosis (Figure 4). Cell cycle findings showed similar results in apoptosis (data not shown).

**DISCUSSION**

An ideal chemotherapeutic agent should be effective on cancer cells, and it should not affect normal cells. CDDP is a highly effective chemotherapeutic agent widely used for treating various adult and pediatric cancers; however, it has dose-limiting serious adverse effects, including nephrotoxicity, neurotoxicity, and ototoxicity [3]. It has been shown that CDDP has ototoxic effects in many studies [4, 5]. LIPO, a nanomolecule 110 nM diameter, is a liposomal formulation of CDDP, and it should not affect normal cells.

Moreover, LIPO showed anti-tumor effect in CDDP-sensitive- and -resistant ovarian cancer cells since apoptosis was induced by caspases 3, 8, and 9 activation; Bax upregulation; and Bcl-2 downregulation [11]. LIPO caused a synergistic effect combination with doxorubicin and the albumin-bound paclitaxel abraxane. Also, LIPO inhibited ovarian xenograft tumor growth with minimum systemic toxicity in that study.

In an animal study to evaluate the renal toxicities of LIPO and CDDP, it has been shown that LIPO induces less structural and functional damage to the kidneys in mice than CDDP [12]. It was observed that intraperitoneal bolus injection of CDDP and LIPO in rat kidneys resulted in less platinum accumulation with LIPO, although CDDP and LIPO reached the same level of platinum.

**CONCLUSION**

In this study, the anti-tumor and apoptotic effect of LIPO was determined in neuroblastoma cells at a higher dose than CDDP and at later time periods. LIPO caused less apoptotic cell death on cochlear cells than CDDP at anti-tumoral doses, suggesting a lower toxicity in cochlear cells compared to CDDP. Further in vivo comparative studies are needed for understanding the mechanism of ototoxic effects of LIPO versus CDDP [22].

**Ethics Committee Approval:** Authors declared that the research was conducted according to the principles of the World Medical Association Declaration of Helsinki “Ethical Principles for Medical Research Involving Human Subjects”, (amended in October 2013).

**Informed Consent:** N/A.

**Peer-review:** Externally peer-reviewed.


**Acknowledgements:** The authors would like to thank Prof. F. Kalincel for ensuring HEI-OC1 cells.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**REFERENCES**


